Barry Wells, M.D., spent almost 40 years as a urologist and surgeon, specializing in treating kidney stones, urinary tract infections, and urological conditions. Transitioning his focus to gene therapy, he joined Addimmune™, initially contributing to the investor relations team for three years before becoming the Head of Business Development. With a strong belief in the company’s potential to deliver vital cures, Dr. Wells merges his medical background with a keen interest in business and technology. He has established small-business ventures and raised funds for an early-stage AI company, New Sapience. Dr. Wells graduated with honors from the University of Kansas and obtained his M.D. from the Kansas University School of Medicine, followed by a residency in urologic surgery at the University of Maryland Medical Center.